minimally invasive catheter-based targeted delivery

BioCardia, Inc. is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is the CardiAMP autologous mononuclear cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF), manufactured at the patient's bedside using the proprietary CardiAMP cell processing system and delivered via a catheter-based minimally invasive approach. Its allogeneic mesenchymal stem cell platform is advanced as CardiALLO for heart failure and PulmALLO for acute respiratory distress

Read more

allogeneic mesenchymal stem cell manufacturingautologous cell processing at patient bedsidecell therapy development